TransThera Sciences (Nanjing), Inc. (HKG:2617)
Hong Kong · Delayed Price · Currency is HKD 9.38
-0.09 (-0.90%)
Sep 11, 2026, 4:08 PM HKT
HKG:2617 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 35.46 | - | - | 1.18 | 0.12 | |
Revenue Growth | - | - | - | 852.42% | - |
Gross Profit | 35.46 | - | - | 1.18 | 0.12 |
Selling, General & Admin | 50.37 | 54.78 | 47.74 | 39.22 | 49.95 |
Research & Development | 258.26 | 246.76 | 244 | 344.48 | 262.51 |
Other Operating Expenses | 0 | - | 0.03 | 0.01 | 0.02 |
Operating Expenses | 308.63 | 301.54 | 291.77 | 383.7 | 312.48 |
Operating Income | -273.17 | -301.54 | -291.77 | -382.52 | -312.36 |
Interest Expense | -0.13 | -0.12 | -0.2 | -0.25 | -0.18 |
Interest & Investment Income | 8.99 | 4.91 | 2.17 | 12.16 | 6.02 |
Currency Exchange Gain (Loss) | -14.66 | -3.4 | -0.4 | 3.01 | 27.72 |
Other Non Operating Income (Expenses) | 10.06 | 1.24 | 4.91 | 10.11 | 12.57 |
EBT Excluding Unusual Items | -268.91 | -298.91 | -285.29 | -357.49 | -266.24 |
Gain (Loss) on Sale of Investments | 0.3 | 2.95 | 10.68 | 14.09 | 14.3 |
Gain (Loss) on Sale of Assets | 0.05 | -0 | -0 | -0 | -0.01 |
Pretax Income | -268.56 | -295.96 | -274.61 | -343.39 | -251.94 |
Net Income | -268.56 | -295.96 | -274.61 | -343.39 | -251.94 |
Net Income to Common | -268.56 | -295.96 | -274.61 | -343.39 | -251.94 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 399 | 390 | 382 | 381 | 360 |
Shares Outstanding (Diluted) | 399 | 390 | 382 | 381 | 360 |
Shares Change | 4.55% | 2.11% | 0.06% | 5.83% | - |
EPS (Basic) | -0.67 | -0.76 | -0.72 | -0.90 | -0.70 |
EPS (Diluted) | -0.67 | -0.76 | -0.72 | -0.90 | -0.70 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | - | -253.68 | -271.96 | -322.81 | -238.91 |
Free Cash Flow Per Share | - | -0.65 | -0.71 | -0.85 | -0.66 |
Gross Margin | 100.00% | - | - | 100.00% | 100.00% |
Operating Margin | -770.47% | - | - | -32389.58% | -251900.00% |
Profit Margin | -757.48% | - | - | -29076.54% | -203180.65% |
Free Cash Flow Margin | - | - | - | -27333.78% | -192667.74% |
EBITDA | -271.27 | -299.57 | -288.85 | -378.87 | -306.29 |
D&A For EBITDA | 1.9 | 1.97 | 2.92 | 3.66 | 6.07 |
EBIT | -273.17 | -301.54 | -291.77 | -382.52 | -312.36 |